Research map: Trends in publicly subsidized and private access to GLP‐1 medicines indicated for type 2 diabetes in Australia, 2020–2025

Back to the article

Papers in this map

  1. Once-Weekly Semaglutide in Adults with Overweight or Obesity · John P.H. Wilding · 2021 · 5054 citations · Cited by this paper
  2. Relationships among nitrous oxide exposure, neurological injury and biomarkers · 2026 · Related
  3. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes · A. Michael Lincoff · 2023 · 3058 citations · Cited by this paper
  4. Predicting cognitive function in Alzheimer's clinical trials via amyloid β‐protein biomarkers · 2026 · Related
  5. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association · Chiadi E. Ndumele · 2023 · 2076 citations · Cited by this paper
  6. Comparative risk of ventricular arrhythmia and sudden cardiac death among acetylcholinesterase inhibitors in dementia: A population‐based cohort study · 2026 · Related
  7. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes · Vlado Perkovic · 2024 · 1826 citations · Cited by this paper
  8. Pharmacogenomics of dolutegravir: A scoping review of evidence, gaps and clinical implications · 2026 · Related
  9. Changes in lean body mass with glucagon‐like peptide ‐1‐based therapies and mitigation strategies · Ian J. Neeland · 2024 · 382 citations · Cited by this paper
  10. MT‐RNR1 genotype testing for preventing aminoglycoside‐mediated ototoxicity: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx) · 2026 · Related
  11. Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity · Patricia J. Rodriguez · 2025 · 341 citations · Cited by this paper
  12. Population pharmacokinetics and pharmacodynamics of canagliflozin in paediatric patients with type 2 diabetes mellitus · 2026 · Related
  13. GLP-1 Receptor Agonist Discontinuation Among Patients With Obesity and/or Type 2 Diabetes · Duy Do · 2024 · 206 citations · Cited by this paper
  14. Analysis of spontaneous reports of suspected adverse reactions related to medical cannabis from the Italian Phytovigilance System · 2026 · Related
  15. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes · Areesha Moiz · 2025 · 144 citations · Cited by this paper
  16. A university‐certified course on dossier assessment for regulatory scientists in Africa—Reporting on our 5‐year experience · 2026 · Related
  17. The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions · Areesha Moiz · 2025 · 139 citations · Cited by this paper
  18. Perceptions of prescribing violations by doctors: A qualitative study using semi‐structured interviews · 2026 · Related
  19. Semaglutide (Ozempic®) Use in Denmark 2018 Through 2023 ‒ User Trends and off-Label Prescribing for Weight Loss · Aurelie C. Mailhac · 2024 · 58 citations · Cited by this paper
  20. Impact of cumulative glucocorticoid exposure on vancomycin clearance in hospitalized children: A retrospective cohort study · 2026 · Related
  21. Uptake of and Disparities in Semaglutide and Tirzepatide Prescribing for Obesity in the US · Chungsoo Kim · 2025 · 52 citations · Cited by this paper
  22. GLP-1 Medication Use for Type 2 Diabetes Has Soared · Thomas A. Hegland · 2024 · 48 citations · Cited by this paper
  23. Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (2014–2022) · Jialing Lin · 2023 · 47 citations · Cited by this paper
  24. GLP-1 shortages will not resolve this year, EMA warns, amid concern over off-label use · Elisabeth Mahase · 2024 · 27 citations · Cited by this paper
  25. Diabetes: Doctors are told not to start new patients on GLP-1 agonists because of shortages · Gareth Iacobucci · 2023 · 12 citations · Cited by this paper
  26. The cost-effectiveness of semaglutide in reducing cardiovascular risk among people with overweight and obesity and existing cardiovascular disease, but without diabetes · Ella Zomer · 2024 · 12 citations · Cited by this paper
  27. Incidence of GLP ‐1 receptor agonist use by women of reproductive age attending general practices in Australia, 2011–2022: a retrospective open cohort study · Kailash Thapaliya · 2025 · 12 citations · Cited by this paper
  28. Utilization and cost of non‐insulin glucose‐lowering drugs in Australia from 2013 to 2023 · Peter Shane Hamblin · 2024 · 11 citations · Cited by this paper
  29. Impact of ADA Guidelines and Medication Shortage on GLP-1 Receptor Agonists Prescribing Trends in the UK: A Time-Series Analysis with Country-Specific Insights · Ahmed R. N. Ibrahim · 2024 · 10 citations · Cited by this paper
  30. Glucagon‐like peptide‐1 receptor agonists discontinuation is higher in individuals with overweight and obesity without type 2 diabetes · Gregory J. Grosicki · 2025 · 10 citations · Cited by this paper
  31. The role of GLP ‐1 receptor agonists in the management of obesity: risks and opportunities for the Australian health care system · Christopher Kanellis · 2025 · 10 citations · Cited by this paper
  32. The impact of GLP-1 receptor agonist shortages on glycaemic Control: Findings from an Australian specialist diabetes clinic · Natalie Nanayakkara · 2024 · 9 citations · Cited by this paper
  33. Use of, time to, and type of first add‐on anti‐hyperglycaemic therapy to metformin in Australia, 2018–2022 · Tamara Y. Milder · 2024 · 5 citations · Cited by this paper
  34. Initiators of Semaglutide in General Practice in New South Wales, 2020–2023: A Retrospective Cohort Study · Nicholas I-Hsien Kuo · 2026 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)